The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay.
Matthew O. Burrell
Research Funding - DiaTech Oncology
Michael Stany
Research Funding - DiaTech Oncology
James Rutledge
Other Remuneration - DiaTech Oncology
Emery Manuel Salom
Research Funding - DiaTech Oncology
Manuel Penalver
Research Funding - DiaTech Oncology
Allan Hallquist
Employment or Leadership Position - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Other Remuneration - DiaTech Oncology
Cary A. Presant
Employment or Leadership Position - DiaTech Oncology
Consultant or Advisory Role - DiaTech Oncology
Stock Ownership - DiaTech Oncology
Research Funding - DiaTech Oncology